stockrow
Friday 6 November 2026
Export CLGN’s income statement to Excel — free account
CollPlant Biotechnologies Ltd. Sponsored ADR
CLGN Healthcare Biotechnology
CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024.
- Revenue
- −39.7%
- EPS
- +32.5%
- Free cash flow
- +5.08%
Quarter to June 2026, against a year earlier
3.85
0.09
−2.28%
Follow CLGN
Alert me
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) P/E ratio
CollPlant Biotechnologies Ltd. Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 118× (October 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 74.4× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 8.9× | 197.83% |
| FY2016 | 3.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 35 more quarters | Free account |
Against its own ten years
Low 0.0×
High 118×
Ten-year median
0.0×
Current reading's percentile
86
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LEXX Lexaria Bioscience Corp. compare | n/m |
| KPRX Kiora Pharmaceuticals, Inc. compare | n/m |
| CRIS Curis, Inc. compare | n/m |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR | n/m |
| TCRT Alaunos Therapeutics, Inc. compare | n/m |
| SNGX Soligenix Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| VTGN VistaGen Therapeutics, Inc. compare | n/m |
| TOVX Theriva Biologics, Inc. compare | n/m |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)